Future studies should evaluate the efficacy of sEH inhibition once periodontal disease is established, as well as focus on dose optimization, long-term safety, and potential synergistic effects with current osteoporosis therapies to better define the translational relevance of these findings. Here, EPHX2 is linked to periodontal disorder.